Wilmington, MA. BALB/c mice were obtained from The Jackson Laboratory, Bar Harbor, ME.
Bacterial Strains and Growth Conditions. S. pneumoniae strains included type 3 strains
WU2 (11) and A66 (18) , and a type 5 strain (12) , which were all kept virulent by mouse passage, and the unencapsulated strain R36A originally derived from the type 2 strain D39 (18) . A66 and D39 were obtained from Dr. M. McCarty and R36A from Dr. A. Tomasz at The Rockefeller University. Clinical isolates of types 1, 3, 6A, 8, 9V, 10, 14, 19F, and 23F were obtained from Barry Gray, University of Alabama in Birmingham. Cultures were maintained and grown as previously described (11) . Log phase bacteria at 108/ml were harvested from 7 ml of broth (Todd-Hewitt supplemented with 0.5% yeast extract) by centrifugation (4,000 g, 10 min, 4°C) and suspended in Ringer's lactate for injection into mice, or 1% phosphate-buffered saline (PBS) for use in the binding assay. Alternatively, 100 ml of a 10S/ml culture was maintained at 60°C for 60 min and the heat-killed organisms, washed twice with Ringer's lactate, were resuspended at a final concentration of 109 cells/ml as determined by optical density at 420 nm (optical density [OD] of 1 = 2 × 10 s colony-forming units [CFU]/ml), and checked for sterility by plating a sample on blood agar. The killed bacteria were stored as 5-mi aliquots at -70°C.
Preparation ofMonoclonal Antipneuraococcal Antibodies. Mice were given four weekly intravenous injections of 2 x l0 s heat-killed R36A in 0.2 ml of Ringer's lactate. Mice were killed 5 d after the last immunization. Spleen cells from immunized mice were fused with the non-Ig-producing mouse myeloma line P3-X63-Ag. 8 .653 using polyethylene glycol 4000 (Fisher Scientific Co., Pittsburgh, PA) as described previously (19, 20) .
After 2-3 wk, culture supernatants were screened for antibody activity against PC as described previously (21) . To assay for antibody to R36A, polystyrene microtiter plates were coated with heat-killed R36A by adding 100 #1 of l0 s cells/ml in PBS to each well. The plate was centrifuged at 550 g for 15 min, washed three times with PBS, and flooded with 1% bovine serum albumin (BSA) in PBS for 4 h at 4°C to block unreacted sites. The remainder of the enzyme-linked immunosorbent assay (ELISA) for anti-R36A antibody was carried out using alkaline phosphatase (AP) anti-mouse Igs as described previously for the anti-PC ELISA (19, 20) .
Hybridomas that secreted antibodies reacting with R36A but not PC were chosen for further study and recloned by limiting dilution on syngeneic normal mouse peritoneal feeder cells. The Ig isotypes of the hybridoma antibodies were determined at this stage using AP-labeled goat antibodies specific for mouse #, 3' I, 72a, ~2b, ~,3, a, x, and ~ chain determinants as previously described (19, 20) .
After expansion of positive reclones, 10-30 million cells were injected intraperitoneally into either syngeneic or nude mice previously primed with pristane (Aldrich Chemical Co., Milwaukee, WI.). Ascites were harvested and the amount of R36A-binding antibody was determined in a quantitative ELISA assay (22) using anti-PC antibodies as standards. Ascites were ammonium sulfate precipitated and again quantitated for anti-R36A-binding antibody. The anti-PC, T15-positive antibody, 22.1A4, was provided by Dr. Latham Claflin, University of Michigan, Ann Arbor, MI (23) .
Assay for Antipneuraococcal Surface Binding Capacity. Hybridoma antibodies were chloramine T-labeled with a~sI (24) for use in a surface binding assay described previously (12) to determine their ability to bind to 10 7 CFU in 0.3 ml. In this assay, ~TCoCls chelated with 0.1 mM diethylenetriamine pentaacetic acid was used as a volume marker (12) . Various strains and serotypes of viable pneumococci were used to determine their relative abilities to bind the l~I-labeled antibody. In some experiments the heat-killed R36A was treated wth 2.5 mg/ml pepsin at 37°C, pH 2.0, for 3 h or with 2 mg/ml trypsin at 37°C, pH 7.5, for 1 h. Before use in the assay, the pH of the pepsin-treated samples was neutralized with 1 N NaOH (25) and the bacteria were washed three times in PBS. Similarly at the end of the incubation with trypsin, the effectiveness of the trypsin was blocked with soybean trypsin inhibitor (Sigma Chemical Co., St. Louis, MO) and the bacteria were washed three times with PBS. Control bacteria received the same treatments minus the pepsin or trypsin.
This assay was also used to test for competitive binding among the hybridoma antibodies to pneumococci. In this case various unlabeled antibodies were used to inhibit the binding of the labeled antibody to pneumococci.
Inhibition
Assay. An ELISA procedure was developed to determine the ability of various pneumococcal cell components to block the binding of the hybridoma antibodies to heat-killed R36A cells. Materials tested included PC (Sigma Chemical Co.), type 3 capsular polysaccharide (from Phillip Baker, NIH), and C-polysaccharide (from John Volanakis, University of Alabama in Birmingham). After coating (with heat-killed R36A) and blocking of microtiter plates with BSA as described above, 100 ttl of 1% BSA were added to all wells. Then 50 ttl of PBS containing a potential inhibitor were added to the first well and diluted threefold through seven wells using 50 #1 dilution wands (Dynatech Laboratories, Inc., Alexandria, VA). Samples were always assayed in duplicate. The eighth well in each row served as an uninhibited control. Next, 50 #1 of a standardized concentration of hybridoma antibody from culture supernatants were added to all wells. Plates were incubated overnight at 4°C, washed three times with PBS, and developed with AP-conjugated goat anti-mouse antibody and AP substrate as described above. The OD, at 405 nm, of each well relative to the OD of the positive control was plotted.
Preparation of Bacterial Lysate.
A modification of the procedure described by Saunders and Guild (26) was used to lyse pneumococci. Briefly, R36A was grown to -1 x 109 cells/ ml in 500 ml of medium. Cells were harvested by centrifugation, washed once with PBS, and resuspended in 1.5 ml of lysis buffer, 0.1% sodium deoxycholate, 0.01% sodium dodecyl sulfate, and 0.15 M sodium citrate. After 5 min at 37 ° C, 2.5 ml of dilution buffer (0.15 M NaC1 and 0.015 M sodium citrate) was added. The lysate was dialyzed against three changes of PBS at 4°C and centrifuged at 10,000 g for 10 min to remove insoluble material. The amount of protein in the lysate was determined by a Bio-Rad microassay (Bio-Rad Laboratories, Richmond, CA). The lysate was aliquoted and stored at -20°C until use.
Trypsin Treatment of Lysate. In some experiments, we trypsin treated the R36A lysate before using it in the ELISA inhibition assay. The lysate was divided into two 300-td samples. To one sample, 50 ttl of a 2 mg/ml solution of trypsin was added while the other sample received 50 td of PBS without trypsin. The mixtures were incubated for 2 h at 37 °C, at which time 10 ttl of soybean trypsin inhibitor (Sigma Chemical Co.) was added to both samples.
Mouse Protection Tests.
Mice were injected intraperitoneally with various concentrations of antibody diluted in 2% fetal calf serum (FCS)-Ringer's lactate 1 h before intravenous challenge with 5-10 times the LD~0 of bacteria. Control mice received diluent alone 1 h before challenge, hnmediately after challenging, samples of the inoculum were diluted and plated to determine the CFU. Deaths were recorded at 24-h intervals. Although most deaths occurred on days 2 and 3, the mice were observed for 10 d. The dose for each of the hybridoma antibodies that protected 50% of infected mice (PD.~0) was calculated by the method of Reed and Muench (27) .
Results
Antibody Characterization. Cells from the fusion of P3-XB3-Ag.8.653 with anti-R36A-immune CBA/N spleen cells were plated into 192 wells. Of these 192, 170 (88.5%) contained growing hybrids. A total of 42 (21.9%) hybrids produced antibody that bound to R36A, and 17 of these produced antibody that did not bind PC. Three of these latter hybrids were recloned and expanded for further study: Xi64 (IgM,K), Xi69 (IgM,K), and Xi126 (IgG2b,r). Using the same procedures, hybridomas were produced from the fusion of spleen cells from a BALB/c mouse that had been immunized with R36A. Of 92 growing hybrids, 14 produced antibody that bound R36A. The antibody produced by two of these failed to bind to PC. One of these latter hybrids was recloned and designated HPR36A (IgM,K).
Lack of Reactivity with Polysaccharides. Possible reactivity of Xi126, Xi64, and
Xi69 antibodies with pneumococcal cell wall and capsular polysaccharides was assessed by using these materials to attempt inhibition of the binding of the hybridoma antibodies to R36A. By this assay all three antibodies failed to show reactivity with free PC, C-polysaccharide, or type 3 pneumococcal polysaccharide (Fig. 1 ). An IgG3 anti-PC antibody, 59.6C5 (23) , was included as a control. Both PC and C-polysaccharide inhibited the binding of the anti-PC antibody to R36A. The less complete inhibition of the binding of this antibody to R36A by type 3 polysaccharide was probably due to a low level of contaminating C-polysaccharide in the type 3 preparation.
Supernatant from a culture of R36A failed to inhibit the binding of these antibodies, indicating that the antigen they detect is neither released into the medium during bacterial growth, nor acquired from it.
Antigen Characterization. The ability of all four non-PC-binding antibodies to bind heat-killed R36A was greatly reduced or eliminated by treating the killed bacteria with pepsin or trypsin ( Table I ). The anti-PC antibody, 22.1A4, bound slightly better to pepsin-or trypsin-treated than to normal cells. These results indicate that the non-PC-binding antibodies recognized a cell surface determinant that was polypeptide associated.
In the case of antibody Xi126, we demonstrated that its target is actually protein and not simply a carbohydrate held to the cell surface by a proteasesensitive polypeptide. We obtained this result using a crude lysate of R36A that could inhibit the binding of Xi 126 antibodies to R36A, as measured by ELISA. When the crude lysate was treated with trypsin, we observed a 10-fold reduction in its ability to block the binding of Xi126 to R36A (Fig. 2) . The same trypsintreated lysate retained its ability to block the binding of 59.6C5 to the PCcontaining cell wall carbohydrate of heat-killed R36A.
Binding of Antibody to Pneumococcal Strains. Live pneumococci of various strains and serotypes were used to determine the binding capacity of ~25I-labeled antibodies. As can be seen in Fig. 3 , these antibodies vary in their ability to bind different pneumococci, indicating that they have different specificities. Antibody Xi69 appeared to be the most cross-reactive. The binding of each of the four antibodies was greatest to strain D39, which was the parental strain of R36A. As a control we included the IgM anti-PC hybridoma, 22.1A4 (23) , which showed about 14% binding to all of the pneumococcal isolates (data not shown). Binding of all four antibodies to the rough strain R36A was between 50 and 60% (data not shown).
Competitive Inhibition of Binding to R36A. A competitive inhibition assay (Fig.   4 ) indicated that the four hybridoma antibodies bound different epitopes on R36A. Although some of the four antibodies competed with others in the assay, the relative inhibitory capacities of the four antibodies were different depending on which antibody's binding to R36A was being inhibited. The anti-PC antibody, 22.1A4 (23) with an LDs0 of 101 in unprotected CBA/N mice. The protective effects of these antibodies were also apparent when non-xid Swiss mice were used; 20 #g of Xi64 and Xi126 were each able to protect against at least 100 (10 LDs0) A66 type 3 S. pneumoniae. This type 3 strain is even more virulent than WU2 (12) . Hybridoma antibody Xi 126 was also protective against fatal infection with the type 2 strain D39 (Table I ). The possibility that some of the antiprotein hybridoma antibodies might be protective against D39 was anticipated since D39 was the parent of the rough strain R36A, against which the hybridoma antibodies were prepared. The higher PDs0 of Xi126 against D39 as compared with WU2 may be due to a greater virulence of D39 than WU2 in xid mice. This would be consistent with the observations that anti-PC antibody 22.1A4 failed to be protective against D39 infection even at doses of 200 #g/ml, and that >10 times as much of the IgG1 anti-PC hybridoma, antibody 159.4D5, was required to protect against D39 as compared with WU2.
Like anti-PC antibodies (12), the antiprotein antibodies are apparently not protective against all of the pneumococcai strains to which they bind, since 200 #g of either Xi64 or Xi126 was not able to protect mice from the type 5 or type 6A strains that were tested in the experiment shown in Fig. 3 .
Discussion
We have demonstrated that two hybridoma antibodies that appear to bind pneumococcal surface proteins can protect mice from experimental infection with S. pneumoniae strains WU2, A66, and D39. We were surprised by the fact that even antiprotein antibodies raised against an unencapsulated laboratory strain of pneumococci that had not been passaged through mice for 40 years, would be protective against any virulent pneumococci.
The fact that these antibodies were not protective against tWO of the pneumococcal strains tested may relate in part to differences in virulence of the different pneumococcal strains for mice. Alternatively, the lack of the ability of these antiprotein antibodies to protect against all strains may be due to an inability of the antibodies to adequately bind the proteins on those strains. We are attempting to test this possibility by raising antiprotein antibodies to the pneumococcal strains our present antibodies fail to protect against. All four of our hybridoma antibodies to pneumococcal surface proteins, including the two antibodies that protect against pneumococcal infection, appeared to detect closely associated epitopes since some of them were able to cross-inhibit the binding of the others. The relative ability of the four antibodies to inhibit the binding of each other to R36A differed markedly, indicating that their different inhibitory capacities were not simply the result of different affinities for the same determinant. It seems that the inhibition may be due to a complex pattern of steric hinderance. The conclusion that the antibodies have different specificities was further supported by their showing different patterns of reactivity with a panel of pneumococcal isolates.
An eventual understanding of the nature of the antigen(s) recognized and the protective mechanisms involved could lead to the development of a pneumococcal vaccine containing protein antigens. Such a vaccine would be particularly important for the immunization of infants (a high risk group for pneumococcal infections) who fail to make adequate protective responses to the pneumococcal capsular polysaccharides that constitute the current vaccines (28) (29) (30) . Although vaccines containing the capsular antigens are highly effective immunogens in adults (1), they fail to elicit adequate protective responses in very young children (28) , probably because children make extremely low anticarbohydrate responses in general until they are at least 1 to 2 yr old (29) (30) (31) (32) . Since infants are generally responsive to protein antigens (33) , an effective protein based vaccine would be more appropriate.
The failure to detect protective antibodies to noncapsular antigens in most previous studies might be partly because of the higher protection afforded by anticapsular antibodies (1-3) and partly because, when presented with the whole pneumococcus, containing many other antigenic structures, the protein antigens might not have been very immunogenic. This latter interpretation is consistent with our observation that a higher frequency of the anti-R36A hybridomas were directed against non-PC determinants when we immunized the xid mouse, which has great difficulty producing antibodies to carbohydrates, than when we used BALB/c mice. In this case the mechanism resulting in poor antibody responses to proteins on whole pneumococci may relate in part to the fact that the dominant antibody responses to a complex antigen tend to inhibit primary responses by other B cell clones (25, (34) (35) (36) (37) . Of particular interest is the fact that when rabbits are immunized with heat-killed streptococci, as much as 95% of the antibody can be directed against the group-specific polysaccharide, leaving 5% directed against other internal and external molecules on the bacterium (25, 38) .
Another possibility is that the capsule may block the antigenicity of cell wall antigens by simply covering them up. We recently observed that when xid mice are immunized with smooth rather than rough pneumococci, very few hybridomas producing antibody to either surface proteins or PC were obtained (McDaniel, Scott and Briles, unpublished results).
Regardless of why the protective potential of these antibodies was not observed in previous studies, we hope that a vaccine containing cell wall proteins, free from other pneumococcal antigens will elicit protection against pneumococci. Recently, a similar strategy has been proposed for other pathogens such as Haemophilus influenzae (39) , where infants also fail to respond to the polysaccharide capsular antigens (32).
Summary
Monoclonal antibodies were raised against surface determinants of Streptococcus pneumoniae by hyperimmunizing X-linked immunodeficient (xid) CBA/N mice with the heat-killed rough strain R36A. 17 hybridomas produced antibody that bound intact R36A and did not cross-react with phosphocholine, an antigen common in the cell wall of all S. pneumoniae. The antibody produced by at least two of these hybridomas, Xi64 (IgM) and Xi126 (IgG2b), could protect mice from a lethal intravenous challenge of type 3 S. pneumoniae strains WU2 and A66 and of the type 2 strain D39. The minimum amount of antibody required to protect xid mice from 100 WU2 was 4.5 #g/mouse for Xi64 and 2.6 #g/ mouse for Xi126. Free phosphocholine, C-polysaccharide, and type 3 capsular polysaccharide all failed to inhibit the binding of Xi64 or Xi 126 to R36A. These antibodies appeared to bind surface polypeptides, since treatment of R36A with either pepsin or trypsin, or of R36A lysate with trypsin, effectively eliminated the ability of Xi64 and Xi 126 to bind antigens in these preparations. Binding studies indicated that these two antibodies recognized different epitopes that were expressed on several but not all serotypes of pneumococci.
